These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. New CARs on and off the road: challenges and new developments in CAR-T cell therapy. Wehrli M; Maus MV Curr Opin Pharmacol; 2021 Aug; 59():116-126. PubMed ID: 34198161 [TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy. Srivastava S; Riddell SR J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388 [TBL] [Abstract][Full Text] [Related]
8. Multipurposing CARs: Same engine, different vehicles. Hossian AKMN; Hackett CS; Brentjens RJ; Rafiq S Mol Ther; 2022 Apr; 30(4):1381-1395. PubMed ID: 35151842 [TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Ramos CA; Dotti G Expert Opin Biol Ther; 2011 Jul; 11(7):855-73. PubMed ID: 21463133 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
12. Intelligent cell-based therapies for cancer and autoimmune disorders. Chen R; Jing J; Siwko S; Huang Y; Zhou Y Curr Opin Biotechnol; 2020 Dec; 66():207-216. PubMed ID: 32956902 [TBL] [Abstract][Full Text] [Related]
13. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers. Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664 [TBL] [Abstract][Full Text] [Related]
14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells. Morgan MA; Büning H; Sauer M; Schambach A Front Immunol; 2020; 11():1965. PubMed ID: 32903482 [TBL] [Abstract][Full Text] [Related]
15. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy. Cortés-Selva D; Dasgupta B; Singh S; Grewal IS Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
17. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
18. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy. Huang D; Miller M; Ashok B; Jain S; Peppas NA Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148 [TBL] [Abstract][Full Text] [Related]
19. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138 [TBL] [Abstract][Full Text] [Related]